New Desheng's core advantage in supplying EPS-G7 and DGGR substrates

In the field of in vitro diagnostic materials, EPS-G7 amylase substrate and DGGR lipase substrate are key components in pancreatic disease diagnostic kits. For a long time, the synthesis technology of these two high-end enzyme substrates has been mastered by a few overseas companies, and domestic IVD production enterprises face practical problems such as long procurement cycles, high costs, and unstable supply chains. Hubei Xindesheng Material Technology Co., Ltd. has achieved technological breakthroughs in the synthesis and mass production of EPS-G7 and DGGR through continuous process research, forming multiple advantages in localized production.

Breakthroughs in independent processes and mastery of key technologies

The molecular structures of EPS-G7 and DGGR are complex, with multiple synthesis steps and difficult purification, requiring strict process control. The technological accumulation and patent layout of overseas enterprises in this field have formed certain barriers to entry. Based on years of research and development experience in the field of chromogenic substrates, Xindesheng has systematically optimized the synthesis routes of EPS-G7 and DGGR, successfully overcoming the difficulties of preparing key intermediates and purifying final products, and achieving stable mass production of products at the kilogram level. This breakthrough has enabled New Desheng to have independent production capabilities for these two products and master the full process technology from raw materials to finished products.

Performance comparable to imported, reliable quality

The purity of New Desheng EPS-G7 and DGGR products has reached a high level. EPS-G7 has been tested in multiple batches and its purity can be stably controlled at over 98%, with good control of key impurity levels; DGGR products have also met the relevant requirements in terms of isomer content and free chromophore control. The stability of the product has been verified through long-term monitoring, and the consistency between batches meets the requirements for the production of diagnostic reagents. The results of clinical sample equivalence testing show that the detection values of New Desheng products match the trend of imported brands, with a relatively small deviation controlled within a small range, and have the technical feasibility of replacing imported products for clinical testing.

High cost-effectiveness advantage, reducing procurement costs

As a local manufacturer, New Desheng's product pricing does not require the addition of tariffs and intermediary premiums. The domestically produced EPS-G7 and DGGR substrates can significantly reduce the raw material procurement costs of downstream reagent production enterprises. For IVD production enterprises that need to face the pressure of centralized procurement prices, optimizing raw material costs can help enhance the profit margin and market competitiveness of their products.

Worry free local supply, shortened delivery cycle

The layout of domestic production bases makes supply chain management simpler. After the customer places an order, New Desheng products can be shipped directly from the local warehouse without going through international logistics, customs clearance, and other processes, greatly shortening the delivery cycle. For urgent replenishment or urgent orders, localized production can respond faster and effectively reduce customer inventory pressure. In the context of global supply chain fluctuations, local supply channels also provide customers with additional supply guarantees.

One stop raw material matching, convenient service

New Desheng's product line covers multiple categories, including biological buffering agents (Tris, HEPES, MOPS, etc.), chromogenic substrates (TOOS, MAOS, etc.), and enzyme preparations. For the development and production of diagnostic reagents for pancreatitis, Xindesheng not only provides two core substrates, EPS-G7 and DGGR, but also synchronously provides the required buffer raw materials to help customers simplify supplier management and reduce comprehensive procurement costs. The current production capacity of EPS-G7 substrate produced by Desheng has reached 400 grams per month and will be increased to the kilogram level in the near future; The substrate production capacity of DGGR is 30 grams per month, which can meet the demand for small and medium-sized batch supply. With the gradual release of production capacity and continuous iteration of technology, Xindesheng will form a more complete localized product matrix in the field of enzymatic substrates.